文献速递糖尿病

三种不同制剂门冬胰岛素的药代与药效学:1型糖尿病男性的随机双盲交叉研究

Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2020-12-16

该单中心随机双盲三周期交叉研究在19名1型糖尿病男性中比较了新型门冬胰岛素制剂AT247与NovoRapid及Fiasp的单次0.3单位/kg皮下注射的药代与药效学。结果显示AT247较两对照起效更快、早期暴露更高且降糖作用更强,暴露消退也更早,但降糖作用持续时间无显著差异。

要点

  • AT247较NovoRapid和Fiasp胰岛素出现更早、起效更快。
  • AT247早期暴露和早期降糖作用显著优于两对照制剂。
  • AT247暴露消退更早,但降糖持续时间无显著差异。

核心结论

  • AT247较NovoRapid和Fiasp胰岛素出现、暴露及消退更早,早期降糖作用更强,是有前景的二代餐时胰岛素类似物候选。

研究设计与样本

  • 单中心、随机、双盲、三周期交叉研究,纳入19名1型糖尿病男性,单次0.3单位/kg皮下注射,正葡萄糖钳夹持续最长8小时。

主要发现

  • AT247胰岛素出现较NovoRapid提前12分钟(95%CI -14至-8,P=0.0004),较Fiasp提前2分钟(95%CI -5至-2,P=0.0003)。
  • AT247起效较NovoRapid提前23分钟(95%CI -37至-15,P=0.0004),较Fiasp提前9分钟(95%CI -11至-3,P=0.0006)。
  • 0-60分钟AT247的胰岛素暴露AUC较NovoRapid治疗比为2.3(95%CI 1.9至2.9),较Fiasp为1.5(95%CI 1.3至1.8)。
  • 0-60分钟AT247的降糖效应AUC较NovoRapid治疗比为2.8(95%CI 2.0至5.5),较Fiasp为1.7(95%CI 1.3至2.3)。
  • AT247暴露消退较NovoRapid提前32分钟(95%CI -58至-15,P=0.0015),较Fiasp提前27分钟(95%CI -85至-15,P=0.0017);降糖持续时间(至后期半最大效应时间)无显著差异。

临床怎么用

  • AT247可能通过更早的胰岛素暴露和更强早期降糖作用改善餐后血糖控制,但需进一步研究确认临床获益。

局限性

  • 研究仅纳入19名1型糖尿病男性,样本量小且人群受限,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the pharmacokinetic and pharmacodynamic properties and safety of a novel formulation of insulin aspart (AT247) versus two currently marketed insulin aspart formulations (NovoRapid [IAsp] and Fiasp [faster IAsp]). RESEARCH DESIGN AND METHODS: This single-center, randomized, double-blind, three-period, crossover study was conducted in 19 men with type 1 diabetes, receiving single dosing of trial products (0.3 units/kg) in a random order on three visits. Pharmacokinetics and pharmacodynamics were assessed during a euglycemic clamp lasting up to 8 h. RESULTS: Onset of insulin appearance was earlier for AT247 compared with IAsp (-12 min [95% CI -14; -8], P = 0.0004) and faster IAsp (-2 min [-5; -2], P = 0.0003). Onset of action was accelerated compared with IAsp (-23 min [-37; -15], P = 0.0004) and faster IAsp (-9 min [-11; -3], P = 0.0006). Within the first 60 min, a higher exposure was observed for AT247 compared with IAsp by the area under the curve (AUC) glucose infusion rate (GIR) from 0 to 60 min (AUCAsp0-60min: treatment ratio vs. IAsp 2.3 [1.9; 2.9] vs. faster IAsp 1.5 [1.3; 1.8]), which was underpinned by a greater early glucose-lowering effect (AUCGIR,0-60min: treatment ratio vs. IAsp 2.8 [2.0; 5.5] vs. faster IAsp 1.7 [1.3; 2.3]). Furthermore, an earlier offset of exposure was observed for AT247 compared with IAsp (-32 min [-58; -15], P = 0.0015) and faster IAsp (-27 min [-85; -15], P = 0.0017), while duration of the glucose-lowering effect, measured by time to late half-maximum effect, did not differ significantly. CONCLUSIONS: AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with IAsp and faster IAsp. It therefore represents a promising candidate in the pursuit for second-generation prandial insulin analogs to improve postprandial glycemic control.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Svehlikova E, Mursic I, Augustin T, et al. Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes. Diabetes Care. 2020. PMID: 33328285. doi:10.2337/dc20-1017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。